跳至主要内容
临床试验/NCT06264219
NCT06264219招募中1 期

"Restoration of the Gut Microbiome After Cesarean Section (RestoreGut)" - A Double-blinded Randomized Placebo-controlled Trial

Jakob Stokholm3 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2024年8月2日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
80
试验地点
3
主要终点
Microbial compositional differences to placebo-treated infants

研究概览

简要总结

This study aims to develop a therapy for restoring the gut microbiome in infants born via CS. The Study will conduct a randomized, placebo-controlled feasibility trial to assess the ability of microbiome restoration by FMT and FVT in infants born by cesarean section.

详细描述

When a child is born vaginally, the passage through the birth canal provides the first and very important bacterial colonization. As the child ages, various environmental exposures, such as dietary changes and the presence of older siblings in the home, facilitate a natural maturation of the child's gut microbiome, providing a vast and continuous stimulation of the child's developing immune system. However, factors such as mode of delivery and intrapartum antibiotics can perturb this natural developmental process and cause long-term microbial derangements. The prevalence of cesarean section (CS) birth has increased globally in recent decades, and with it, antibiotic treatment to prevent perinatal infection. Similar patterns have occurred for the prevalence of chronic childhood disease, particularly asthma, with an estimated 300 million asthmatic cases worldwide.

The hypothesis is that early intervention with mother-to-infant FMT can restore a CS-perturbed microbiome to a normal microbial trajectory. Another hypothesis is that seeding the virome fraction (FVT) will cause the neonate's microbiome to resemble the mother's since the transferred phages are enriched and preserved in the intestinal mucus layer, thereby providing the recipient with selective antimicrobial protection while allowing species resembling the mother's own to establish during subsequent bacterial transmission.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Gestational age < week 38+0 days
  • Proficient in spoken/written Danish
  • Single pregnancy (no twins or triplets)
  • Pre-pregnancy BMI between 18.5 and 35 kg/m2
  • No chronic intestinal, endocrine, cardiac, or kidney disorders
  • No known gestational complications (gestational diabetes, preeclampsia, gestational hypothyroidism)
  • No regular use of prescription medication or any drugs that, in the research team's opinion, may interfere with the study's results.
  • Willingness to abstain from giving the child products with probiotics (fermented dairy like yogurt or A38 are allowed).

排除标准

  • Use of antibiotics within one month of stool donation
  • Acute gastroenteritis within one month of stool donation
  • Use of antibiotics within one month of birth
  • Time since last travel abroad relative to data of fecal donation according to the requirements for blood donations ("Regler for tappepauser" - blooddonor.dk)
  • Positive test results for pathogens during donor material screening.
  • Antibiotic treatment at birth (vaginal births only)
  • Spontaneous onset of labor or emergency cesarean section before scheduled cesarean section.
  • Instances of major birth defects or intrauterine growth retardation (IUGR)
  • Infants requiring pediatric support at the time of transplant administration

研究组 & 干预措施

FMT (Fecal microbiota transplantation)

Active Comparator

Mother-to-infant fecal microbiota transplantation

干预措施: Microbiome restoration - FMT (Biological)

FVT (Fecal virome transplantation)

Active Comparator

Mother-to-infant fecal virome transplantation

干预措施: Microbiome restoration - FVT (Biological)

Placebo

Placebo Comparator

Inactive solution buffer placebo

干预措施: Placebo (Biological)

Vaginal control group

Other

Non-randomized control group used for secondary outcomes comparisons.

干预措施: Vaginal birth, untreated control (Other)

结局指标

主要结局

Microbial compositional differences to placebo-treated infants

时间窗: During the first year of life

Intestinal microbiome composition, assessed by metagenomic sequencing of fecal matter bacterial DNA, quantified by beta-diversity indices.

Microbial compositional differences compared with placebo-treated infants

时间窗: At 1 week of age

Intestinal microbiome composition, assessed by metagenomic sequencing of fecal matter bacterial DNA, quantified by beta-diversity indices.

次要结局

  • Microbial compositional resemblance to vaginally-born infants(During the first year of life)
  • Microbial compositional differences compared with placebo-treated infants(During the first year of life)
  • Microbial compositional resemblance to vaginally-born infants(At 1 week of age)
  • Virome compositional differences compared with placebo-treated infants(At 1 week of age)
  • Virome compositional differences compared with placebo-treated infants(During the first year of life)
  • Virome compositional differences compared with vaginally-born infants(At 1 week of age)
  • Virome compositional differences compared with vaginally-born infants(During the first year of life)

研究者

发起方
Jakob Stokholm
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Jakob Stokholm

Professor PhD

Copenhagen Studies on Asthma in Childhood

研究点 (3)

Loading locations...

相似试验